Difference between revisions of "Foregut primary carcinomas"
Jump to navigation
Jump to search
(Created page with "Cancer arising from a '''foregut primary''' can be difficult to definitively categorize on the basis of pathology alone, as their immunostaining patterns significantly ove...") |
(→IHC) |
||
| (17 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
'''Foregut primary carcinomas''' can be difficult to definitively categorize on the basis of [[pathology]] alone, as their [[immunostain]]ing patterns significantly overlap.<ref name=pmid12748245>{{Cite journal | last1 = Lee | first1 = MJ. | last2 = Lee | first2 = HS. | last3 = Kim | first3 = WH. | last4 = Choi | first4 = Y. | last5 = Yang | first5 = M. | title = Expression of mucins and cytokeratins in primary carcinomas of the digestive system. | journal = Mod Pathol | volume = 16 | issue = 5 | pages = 403-10 | month = May | year = 2003 | doi = 10.1097/01.MP.0000067683.84284.66 | PMID = 12748245 }}</ref> | |||
''Foregut primary'' directs to this article. | |||
==Foregut== | |||
The foregut includes the following: | |||
*[[Esophagus]]. | |||
*[[Stomach]]. | |||
*[[Duodenum]], proximal portion - to the ampulla of Vater. | |||
*[[Liver]]. | |||
*[[Gallbladder]]. | |||
*[[Pancreas]].<ref name=pmid23630303>{{cite journal |authors=Jennings RE, Berry AA, Kirkwood-Wilson R, Roberts NA, Hearn T, Salisbury RJ, Blaylock J, Piper Hanley K, Hanley NA |title=Development of the human pancreas from foregut to endocrine commitment |journal=Diabetes |volume=62 |issue=10 |pages=3514–22 |date=October 2013 |pmid=23630303 |pmc=3781486 |doi=10.2337/db12-1479 |url=}}</ref> | |||
*Lower respiratory tract. | |||
==IHC== | |||
Foregut carcinomas are typically: | |||
*CK7 +ve. | |||
*CK20 -ve. | |||
*CDX2 -ve. | |||
*[[HNF-1beta]] +ve (72-87% of cases +ve in one study<ref name=pmid30065837>{{cite journal |authors=Yang MX, Coates RF, Ambaye A, Gardner JA, Zubarick R, Gao Y, Skelly J, Liu JG, Mino-Kenudson M |title=Investigation of HNF-1B as a diagnostic biomarker for pancreatic ductal adenocarcinoma |journal=Biomark Res |volume=6 |issue= |pages=25 |date=2018 |pmid=30065837 |pmc=6062876 |doi=10.1186/s40364-018-0139-6 |url=}}</ref>). | |||
A (query) foregut primary panel for liver lesions: | |||
*AE1/AE3, CK7, CK20, CK19, CDX2, HepPar-1, CA-125, GATA3, PAX8, WT-1, TTF-1. | |||
==See also== | ==See also== | ||
Latest revision as of 15:28, 3 August 2021
Foregut primary carcinomas can be difficult to definitively categorize on the basis of pathology alone, as their immunostaining patterns significantly overlap.[1]
Foregut primary directs to this article.
Foregut
The foregut includes the following:
- Esophagus.
- Stomach.
- Duodenum, proximal portion - to the ampulla of Vater.
- Liver.
- Gallbladder.
- Pancreas.[2]
- Lower respiratory tract.
IHC
Foregut carcinomas are typically:
A (query) foregut primary panel for liver lesions:
- AE1/AE3, CK7, CK20, CK19, CDX2, HepPar-1, CA-125, GATA3, PAX8, WT-1, TTF-1.
See also
References
- ↑ Lee, MJ.; Lee, HS.; Kim, WH.; Choi, Y.; Yang, M. (May 2003). "Expression of mucins and cytokeratins in primary carcinomas of the digestive system.". Mod Pathol 16 (5): 403-10. doi:10.1097/01.MP.0000067683.84284.66. PMID 12748245.
- ↑ Jennings RE, Berry AA, Kirkwood-Wilson R, Roberts NA, Hearn T, Salisbury RJ, Blaylock J, Piper Hanley K, Hanley NA (October 2013). "Development of the human pancreas from foregut to endocrine commitment". Diabetes 62 (10): 3514–22. doi:10.2337/db12-1479. PMC 3781486. PMID 23630303. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3781486/.
- ↑ Yang MX, Coates RF, Ambaye A, Gardner JA, Zubarick R, Gao Y, Skelly J, Liu JG, Mino-Kenudson M (2018). "Investigation of HNF-1B as a diagnostic biomarker for pancreatic ductal adenocarcinoma". Biomark Res 6: 25. doi:10.1186/s40364-018-0139-6. PMC 6062876. PMID 30065837. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062876/.